Never tear us a-PARP: Dealing with DNA lesions during mitosisSchoonen, P. M. & van Vugt, M. A. T. M., 2018, In : Molecular & Cellular Oncology. 5, 1, 4 p., e1382670.
Research output: Contribution to journal › Article › Academic › peer-review
Tumors defective in homologous recombination (HR) are highly sensitive to poly ADP-ribose polymerase (PARP) inhibition, however the cell biological mechanisms underlying this synthetic lethality remain elusive. We recently identified that PARP inhibitor-induced DNA lesions persist until mitosis, subsequently causing mitotic chromatin bridges, multinucleation and apoptosis. Here, we discuss the implications of these findings.
|Number of pages||4|
|Journal||Molecular & Cellular Oncology|
|Publication status||Published - 2018|
- Journal Article, checkpoint, olaparib, Mitosis, PARP, BRCA1/2